secwatch.observer — SEC 8-K summary
======================================

Issuer:     Adaptimmune Therapeutics PLC (—)
CIK:        0001621227
Form:       8-K
Filed at:   2025-09-26T23:59:59+00:00
Accession:  0001104659-25-093882
Event type: regulatory
Sentiment:  negative
Materiality: 0.70
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

Adaptimmune granted Nasdaq extension to Dec 1, 2025 to regain $1 bid compliance
-------------------------------------------------------------------------------

- Nasdaq Hearings Panel granted exception until December 1, 2025 to meet minimum $1.00 bid price per share.
- Notice received on September 22, 2025; failure to comply by deadline will lead to delisting of ADSs.
- If non-compliant by December 1, 2025, trading will be suspended and delisting proceedings will commence.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1621227/000110465925093882/0001104659-25-093882-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1621227/000110465925093882/adap-20250922x8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-093882

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer